Microneedles for Trans / Intradermal Drug Delivery

News provided by

Nov 26, 2014, 07:11 ET

DUBLIN, Nov. 26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Microneedles for Trans / Intradermal Drug Delivery" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Transdermal delivery via microneedles is increasingly gaining traction as one of the more promising drug delivery technologies. Microneedles are of a few hundred microns in size, capable of creating transient pores across the skin by penetrating the stratum corneum layer to deliver molecules. These needles are not big enough to reach the nerve-rich regions of the skin; as a result, the drug delivery is perceived as completely painless and devoid of bleeding. Drugs, vaccines, proteins, peptides and other biomolecules are suitable for delivery using the microneedle technology.

The market is still in its infancy. So far, only one microneedle based delivery device, Soluvia prefilled microinjection system, has reached the market. The vaccine-device combination product was FDA approved in May 2011 for intradermal delivery of Fluzone influenza vaccine. We have identified more than 25 companies, with proprietary microneedle technology, actively working towards the development of microneedle-based drug or vaccine products. Clearside Biomedical, NanoPass Technologies, Corium International, Circassia, Radius Health and Zosano Pharma are examples of companies which are evaluating microneedle based drug/vaccine - device combination products (referred to as products hereafter) in clinical trials.

During the course of our research, we came across 22 products currently in different stages of development. We expect around ten products to be launched by the end of this decade, providing the much needed push to this market. Technological advancements will ensure the development of microneedle systems with improved safety and efficacy profile. As more products move from pipeline to the market, we expect to see an increase in the investment in this area from various quarters.

The Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030' report provides an extensive study in the field of microneedle based delivery systems for therapeutic use. The report covers various aspects, such as, benefits of microneedle assisted drug delivery over conventional needle-syringe system, key industry stakeholders, manufacturing challenges and upcoming opportunities.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION TO MICRONEEDLES

4. MARKET OVERVIEW

5. TECHNOLOGY PROVIDERS

6. ACADEMIA

7. PRODUCT PROFILES

8. CASE STUDIES

9. MARKET FORECAST, 2014-2030

10. SWOT ANALYSIS

11. INTERVIEW TRANSCRIPTS

12. CONCLUSION

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

Companies Mentioned:

10X Technology
3M Drug Delivery Systems
3M Unitek
4P Therapeutics
AAC
AKM
Abingworth
Advanced Technology Ventures
Agate Medical Investments
AllTranz
Alza Corporation
Amspar B.V
Analog Devices
Angiomed
Aphelion Capital
Apogee Technology
Asahi Kasei Pharma Corporation (AKP)
AvagoTechnologies
BB Biotech Ventures
Bausch & Lomb
Becton Dickinson
Biacore
BioMed Ventures
BioSerenTach
Biochemics
Biotech Growth N.V
Bosch
Brandon Capital
Brookside Capital
CEA-LETI
CHL Medical Partners
Canon
Capital Royalty L.P
Carrera
Cerametal
Circassia
Clearside Biomedical
Corium International
Curasen
D-Partners
Debiotech
Denso
Elcam Medical
Enterprise Ireland
Essex Woodlands Health Ventures
Extraject Technologies
F2 Biosciences III, L.P.
Flir Systems
FluGen
Forma Medical
Fraunhofer Institute
Freescale Semiconductor
Fujifilm
GE Sensing
GSK
Georgia Research Alliance Venture Fund
HBM BioVentures
HBM Partners
HLM Venture Partners
Hatteras Venture Partners
HealthCare Ventures
Hewlett Packard
Honeywell
IBM
ImmuPatch
Infineon Technologies
Invensense
Ipsen Pharma
Iscar
Israel HealthCare Ventures (IHCV)
Janisys
Janssen Pharmaceuticals
Kaiser Permanente Ventures
Kenan Flagler Business School Private Equity Fund
Kionix
Knowles Electronics
Knox LLC
Lexmark
Lonza Group Ltd.
MPM Capital
Macroflux Corporation
Measurement Specialities Inc.
Mecaplast
Medicago
Memsic
Mercatus Capital and GITP (Global Innovations & Technology Platform) Investments
Merck
Metalor Dental
MicroCreate B.V
Micropoint Technologies
Mountain Group Capital
Murata
Nanopass
Nemaura Pharma
New Enterprise Associates (NEA)
Nissha Printing Co. Ltd
Nomura Phase4 Ventures
Novartis
Novo Nordisk
Novosanis
ONSET Ventures
Ofer Hi-Tech
Omron
OneVentures
Oxford NanoDelivery
PKA SoftTouch Corp
Panasonic
Par Pharmaceuticals
Philips Medisize
Phillips Plastic Corporation
Phonak AG
Pitango Venture Capital
Pro-micron
ProQuest Investments
Procter & Gamble
Quantum Technology Partners
Radius Health
Robert Bosch
Rolex
RusanoMedInvest (RMI)
ST Microelectronics
Sanofi Pasteur
Santen Inc.
Seco
Seiko Epson
Sensata
Sony
Star Surgical
StrataGent Life Sciences
TechnoPhage
Teva Pharmaceuticals
Texas Instruments
TheraJect
TransDerm Inc.
Triquint
Tyco Electronics
UTC Aerospace
Ulis
Valeritas
Vaxxas
WFD Ventures
Welsh, Carson, Anderson & Stowe (WCAS)
Zosano Pharma
nanoBioSciences